Results 21 to 30 of about 74,894 (355)
Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment : evidence from the RESTORE trial [PDF]
, 2012 Background/aims To evaluate the cost-effectiveness of ranibizumab as either monotherapy or combined with laser therapy, compared with laser monotherapy, in the treatment of diabetic macular oedema (DME) causing visual impairment from a UK healthcare ...
Mitchell, Paul +7 more
core +2 more sources
Фармацевтичний журнал, 2022 Pulmonary arterial hypertension (PAH) is a progressive and debilitating disease that causes the blood vessels in the lungs to thicken and narrow, forcing the heart to pump blood through the lungs at high pressure. In recent years, a significant number
I. S. Datsenko, A. V. Kabachna
doaj +1 more source
The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC [PDF]
, 2017 Background: Immune checkpoint inhibitors improve outcomes compared with chemotherapy in lung cancer. Tumor PD-L1 receptor expression is being studied as a predictive biomarker. The objective of this study was to assess the cost-effectiveness and economic
Abdel-Rahman +25 more
core +3 more sources
Научно-практическая ревматология, 2010 Heavy economic expenses for treatment with genetic engineering biologicals (GEB) in patients with rheumatoid arthritis (RA) determine what strategies are most optimal in terms of both their clinical efficiency and economic constituent should be sought ...
Dmitry Vladimirovich Goryachev +2 more
doaj +1 more source
Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review
Expert Review of Vaccines, 2023 Introduction Studies on economic evaluations of the 13-valent pneumococcal conjugate vaccine (PCV13) have been increasing over the last decade. No systematic reviews have synthesized the evidence of economic evaluations of the PCV13.
Yuanze Du +11 more
doaj +1 more source
Фармацевтичний журнал, 2023 Over the past decades, health policy makers have focused on early diagnosis to introduce targeted and innovative treatments. Early diagnosis of pulmonary arterial hypertension (PAH) is associated with improved long-term survival, so screening high-risk ...
I. S. Datsenko
doaj +1 more source
Фармакоэкономика, 2019 The aim of the review was to analyze the availability of insulin therapy and the ways to improve it in countries with the largest number of patients with diabetes. It was also aimed to assess the medical, social and economic importance of insulin therapy
S. V. Ponomarenko
doaj +1 more source
Risk Equity: A New Proposal [PDF]
, 2007 What does distributive justice require of risk regulators? Various executive orders enjoin health and safety regulators to take account of “distributive impacts,” “equity,” or “environmental justice,” and many scholars endorse these requirements.
Adler, Matthew D.
core +3 more sources
International experience in determining the cost-effectiveness thresholds
Фармакоэкономика, 2019 The article reviews international methodological guidelines, regulatory documents and existing approaches to the determination of the costeffectiveness threshold (CeT), also known as the willingness-to-pay threshold (WTP), the threshold value of the ...
T. P. Bezdenezhnykh +5 more
doaj +1 more source
Calculating QALYs, comparing QALY and DALY calculations [PDF]
Health Policy and Planning, 2006 Quality-adjusted life years (QALYs) have been used in the assessment of health interventions for three decades. The popularity of the QALY approach has been constantly increasing, although the debate on its theoretical underpinnings and practical implications is still ongoing.
openaire +2 more sources